Molecular Diagnostics VL

TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski

(Length of Discussion: 12 min) Alicia Morgans discusses with Mark Markowski details of the TRIUMPH trial, a single-arm, phase II trial, open-label using a PARP inhibitor rucaparib, in the absence of androgen deprivation therapy in men with metastatic hormone-naive prostate cancer. Biographies: Mark Christopher Markowski, MD., Ph.D., is a medical oncologist at the Kimmel Cancer Center at Sibley Mem...

The Role of the PARP Inhibitor in Treating Prostate Cancer: Interview with Joaquin Mateo

Alicia Morgans and Joaquin Mateo discuss mapping the genomic landscape of advanced prostate cancer, and the realization that many patients with advanced forms of prostate cancer have tumors with defects in the repair of DNA damage. And what we observed for the first time is actually that a drug like olaparib, a PARP inhibitor, that has been used in breast or ovarian cancer, were associated to thes...